Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 20 de 1.060
Filter
1.
Rev. bras. cir. plást ; 34(4): 531-538, oct.-dec. 2019. ilus, tab
Article in English, Portuguese | LILACS (Americas) | ID: biblio-1047921

ABSTRACT

O linfoma anaplásico de grandes células associado ao implante de mama (Breast Implant Associated Anaplastic Large Cell Lymphoma - BIA-ALCL) é uma doença maligna recentemente descoberta, rara e possivelmente associada aos implantes mamários texturizados. Essa revisão da literatura teve como objetivo trazer novas atualizações acerca da epidemiologia, fisiopatologia e fatores de risco para desenvolvimento do BIAALCL. Foi realizado o levantamento de dados do período de dezembro de 2018 a fevereiro de 2019, através das bases de dados PUBMED, LILACS e Scielo sendo selecionados 10 artigos publicados entre 2016 e 2018. Foi encontrada uma incidência variando entre 2,8:100.000 a 1:3 milhões de pacientes com implantes mamários. Os dados coletados corroboram para a teoria de que não há uma relação direta de causa e efeito entre os implantes mamários, mormente os texturizados, e o desenvolvimento do BIA-ALCL, podendo esses ser considerados somente como fatores de risco e não agentes causadores. A teoria fisiopatológica mais aceita é a de que os implantes mamários com maior área de superfície levariam a formação de maior biofilme por maior adesão bacteriana gerando inflamação crônica mais proeminente, levando ao gatilho para a transformação maligna das células T. As informações explicitadas nessa revisão devem auxiliar na ampliação de estudos acerca da doença e criação de políticas públicas para a prevenção e diagnóstico precoce de tal enfermidade. Pelos dados encontrados há necessidade de que cirurgiões plásticos realizem acompanhamento mais próximo de seus pacientes, assim como orientem os pacientes antes das cirurgias sobre a existência da doença.


Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a newly discovered and rare cancer possibly associated with textured breast implants. This literature review investigates its epidemiology, pathophysiology, and risk factors. PubMed, LILACS, and SciELO databases were searched from December 2018 to February 2019, and 10 articles published between 2016 and 2018 were selected. The incidence of BIA-ALCL ranged from 2.8:100,000 to 1:3 million breast implants. The obtained data corroborate the hypothesis that there is no direct cause and effect relationship between breast implants, especially textured implants, and BIA-ALCL, and these implants can be considered risk factors but not causative factors. The most accepted hypothesis on disease pathophysiology is that breast implants with larger surface areas may promote bacterial adhesion and biofilm formation, leading to severe chronic inflammation, triggering the malignant transformation of T cells. This review provides knowledge on BIA-ALCL and helps develop and implement public policies for disease prevention and timely diagnosis. The data highlight that long-term follow up is necessary and that surgeons should advise patients of the potential risk of developing BIA-ALCL before performing the implant surgery.


Subject(s)
Humans , History, 21st Century , Lymphoma, Non-Hodgkin , Breast Neoplasms , Lymphoma, T-Cell , Review , Lymphoma, Large-Cell, Anaplastic , Breast Implants , Breast Neoplasms/physiopathology , Hodgkin Disease/physiopathology , Lymphoma, T-Cell/physiopathology , Lymphoma, Large-Cell, Anaplastic/surgery , Lymphoma, Large-Cell, Anaplastic/physiopathology , Breast Implants/statistics & numerical data
2.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 17(3): 72-75, dic.2019. tab, ilus
Article in Spanish | LILACS (Americas), BDNPAR | ID: biblio-1047999

ABSTRACT

La endocarditis trombótica no bacteriana (ETNB) se define como la presencia de trombos estériles sobre las válvulas cardiacas, corresponden a agregados de plaquetas y fibrina no infectados asociados a estados de hipercoagulabilidad como las neoplasias malignas, en donde se denomina también endocarditis marántica. Se presenta el caso de un paciente con historia de síndrome febril prolongado al que se le inició tratamiento antibiótico por una endocarditis infecciosa (EI) por presentar una imagen compatible con vegetación en el ecocardiograma transtorácico. Sin embargo, el paciente persistió febril y sin mejoría clínica, hasta que la biopsia de un ganglio cervical diagnosticó un linfoma de Hodgkin mejorando posteriormente con el tratamiento hemato específico(AU)


Non-bacterial thrombotic endocarditis (NBTE) is defined as the presence of sterile thrombi on the heart valves, correspond to non-infected platelet and fibrin aggregates associated with hypercoagulable states such as malignant neoplasms, which is also called Marantic Endocarditis. We present the case of a patient with a history of prolonged febrile syndrome who underwent antibiotic treatment for an Infective Endocarditis (EI) due to a compatible image with vegetation in the transthoracic echocardiogram. However, the patient persisted feverish and without clinical improvement, until the biopsy of a cervical ganglion diagnosed a Hodgkin lymphoma, improving later with the specific hemato treatment(AU)


Subject(s)
Humans , Male , Adult , Endocarditis, Non-Infective , Lymphoma , Neoplasms , Hodgkin Disease , Thrombophilia
3.
Arch. argent. pediatr ; 117(5): 459-465, oct. 2019. ilus, graf, tab
Article in English, Spanish | LILACS (Americas), BINACIS | ID: biblio-1054961

ABSTRACT

Antecedentes. El linfoma de Hodgkin (LH) es uno de los tipos de cáncer pediátrico con más posibilidades de curación. Sin embargo, es raro entre los niños menores de 5 años, y aún se desconocen los factores pronósticos de la supervivencia debido a su baja frecuencia en este grupo etario. Objetivos. El objetivo de este estudio fue evaluar las características clínicas, los esquemas de tratamiento y el desenlace de los pacientes con LH menores de 5 años. Métodos: se realizó una evaluación retrospectiva de los pacientes con diagnóstico de LH entre 1972 y 2013. Todos los pacientes recibieron quimioterapia, con o sin radioterapia. Resultados. Participaron 102 pacientes; la mediana de edad fue de 4 años (intervalo: 2-4,9). La mediana de seguimiento fue de 13 años. Veintitrés pacientes tenían síntomas B, 15 pacientes tenían neoplasia maligna con gran masa tumoral, y los estadios I y II fueron los más frecuentes. Las tasas de supervivencia global (SG) fueron significativamente diferentes según el estadio del cáncer (p = 0,008). Si bien no se observaron diferencias estadísticamente significativas, la presencia de neoplasia maligna con gran masa tumoral y de síntomas B estuvo asociada con un mal pronóstico. Conclusión. En este estudio unicéntrico se incluyó la mayor cantidad de pacientes con LH menores de 5 años. El estadio fue el principal factor de predicción de SG; por otro lado, la presencia de síntomas B y neoplasia maligna con gran masa tumoral también afectó el pronóstico.


Background. Hodgkin's lymphoma (HL) is one of the most curable pediatric cancers, however it is rare among children under five years of age and prognostic factors for survival rate are still unknown due to low frequency in this age group. Objectives. The aim of this study was to evaluate clinical characteristics, treatment regimens, and outcome of patients under five years of age with HL. Methods. Patients diagnosed with HL between 1972 and 2013 were retrospectively evaluated. All patients were treated with chemotherapy with or without radiotherapy. Results. There were 102 patients with a median age of 4 years (range: 2 to 4.9). The median followup time was 13 years. Twenty-three patients had B symptoms, 15 patients had 'bulky disease' and the most common stages were stage I and II. Overall survival (OS) rates were significantly different according to the stage of the cancer (p = 0.008). Although there were no statistically significant differences; the positivity of 'bulky disease' and B symptoms were associated with poor prognosis. Conclusion. Our single-center study included the largest number of patients under five years of age with HL. The stage was the main predictor for OS; on the other hand, the presence of B symptoms and bulky disease has also affected the prognosis.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Hodgkin Disease , Child , Adolescent , Young Adult
4.
Rev. enferm. Inst. Mex. Seguro Soc ; 27(3): 163-174, Jul-Sep 2019. tab, graf
Article in Spanish | LILACS (Americas), BDENF | ID: biblio-1047308

ABSTRACT

Introducción: el plan de cuidados de enfermería estandarizado (PLACE) es un protocolo específico de cuidados, apropiado para aquellos pacientes que padecen los problemas normales o previsibles relacionados con un diagnóstico concreto o una enfermedad. Objetivo: diseñar un PLACE de quimioterapia, como una propuesta para el profesional de enfermería en la programación de los cuidados. Desarrollo: se presenta el caso de una paciente adulta de 34 años, con diagnóstico médico de linfoma de Hodgkin y tratamiento de quimioterapia, hospitalizada en el servicio de Quimioterapia Ambulatoria. Para la evaluación del estado de la paciente se utilizó la Guía de valoración para el paciente adulto por dominios y clases de la NANDA (North American Nursing Diagnosis Association); con base en un proceso de razonamiento diagnóstico, se jerarquizaron y determinaron los diagnósticos de enfermería, los resultados esperados y las intervenciones de enfermería. Se diseñó un plan de cuidados basado en la interrelación de las taxonomías NANDA, NOC (Nursing Outcomes Classification) y NIC (Nursing Interventions Classification). Derivado del razonamiento diagnóstico, se priorizó el siguiente diagnóstico de enfermería: insomnio R/C factores del entorno M/P dificultad para conciliar el sueño. Conclusión: el plan de cuidados de enfermería con enfoque educativo puede ayudar a mejorar el patrón y la calidad del sueño al disminuir la dificultad para conciliar el sueño. Asimismo un adecuado manejo de la medicación, manejo de la energía y del ambiente en casa y en el hospital favorece un adecuado control de la enfermedad y la recuperación.


Introduction: The standardized nursing care plan (SNCP) is a specific care protocol, appropriate for those patients who suffer from normal or foreseeable problems related to a specific diagnosis or illness. Objective: To design an SNCP with an educational approach aimed at a female adult patient with insomnia, Hodgkin lymphoma and chemotherapy treatment, as a proposal for the nursing professional in the patient care program. Development: It is presented the case of a 34-year-dd female adult patient with a medical diagnosis of Hodgkin lymphoma and chemotherapy treatment, hospitalized in the Outpatient Chemotherapy Service. The NANDA (North American Nursing Diagnosis Association) Assessment Cuide for the Adult Patient by Domains and Classes was used to assess the patient's condition; based on a process of diagnostic reasoning, the nursing diagnoses, expected results and nursing interventions were hierarchized and determined. A care plan was designed based on the interrelation of the NANDA NOC (Nursing Outcomes Classification) and NIC (Nursing Interventions Classification) taxonomies. Derived from the diagnostic reasoning, the following nursing diagnosis was prioritized: Insomnia R/T environmental factors M/B difficulty falling asleep. Conclusión: The nursing care plan with an educational approach can help to improve the pattern and quality of sleep by decreasing the difficulty in falling asleep. Likewise, proper medication management, energy management and the environment at home and in the hospital favors adequate disease control and recovery.


Subject(s)
Humans , Sleep Wake Disorders , Hodgkin Disease , Drug Therapy , Energy Metabolism , Patient Care Bundles , Sleep Initiation and Maintenance Disorders , Nursing Care , Nursing Process , Mexico
6.
Article in English | WPRIM (Western Pacific) | ID: wprim-759745

ABSTRACT

A 40-year-old man presented with pruritic, multiple, variable-sized, erythematous umbilicated papules on the trunk and both extremities for 4 months. He was diagnosed with Hodgkin's lymphoma (stage IIA) after histopathologic examination of a neck mass that developed a month ago. A punch biopsy was performed on his right lower leg. Histological examination showed transepidermal elimination of the degenerated collagen. Masson's trichrome staining was performed to distinguish collagen fibers from the muscular tissue; using Masson's stain, the collagen appeared as a bluish color crossing from the dermis to the epidermis. The diagnosis of acquired reactive perforating collagenosis was made. The skin lesions showed much improvement after 6 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy. Acquired perforating disorders are a group of cutaneous disorders that occur in adults with chronic kidney disease or diabetes mellitus. Cases of acquired perforating disorders associated with Hodgkin's lymphoma have been rarely reported in the English literature. To our knowledge, this is the first case of acquired reactive perforating collagenosis in a Korean patient with Hodgkin's lymphoma.


Subject(s)
Adult , Biopsy , Bleomycin , Collagen , Dacarbazine , Dermis , Diabetes Mellitus , Diagnosis , Doxorubicin , Drug Therapy , Epidermis , Extremities , Hodgkin Disease , Humans , Leg , Neck , Renal Insufficiency, Chronic , Skin , Vinblastine
7.
Blood Research ; : 210-217, 2019.
Article in English | WPRIM (Western Pacific) | ID: wprim-763075

ABSTRACT

BACKGROUND: Classical Hodgkin lymphoma (cHL) is a clinicopathologically unique, aggressive lymphoma arising from germinal center B-cells and is one of the most curable hematological malignancies. This study aimed to determine the clinical course, treatment regimens, response rates, and survival data of patients diagnosed with cHL in a tertiary center. METHODS: A retrospective review was conducted to include patients with a diagnosis of cHL from 2013 to 2017. Data of demographic and clinical characteristics, treatment regimens, and outcomes were collected and analyzed. RESULTS: We recruited 94 patients with a median age of 27.0 [interquartile range (IQR), 12] years. Most of the patients were male (61.7%) and 73.4% were ethnic Malay. Nodular sclerosis was the most common histology (77.6%), followed by mixed cellularity (6.4%) and others (16%). The median follow-up time was 28.0 (IQR, 32) months. All patients received chemotherapy but only 13.8% received radiotherapy as consolidation. The doxorubicin-bleomycin-vinblastine-dacarbazine regimen was the most common (85.1%), followed by the escalated bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristineprednisolone-procarbazine regimen (14.9%). Following treatment, 76.1% of patients achieved complete response. The 2-year overall survival (OS) and progression-free survival (PFS) of the entire cohort were 96.5% and 71.1%, respectively. The 2-year OS and PFS for advanced-stage disease were 93.9% and 62.8%, compared to 100% and 82.7% for early-stage disease, respectively (P=0.252 and P=0.052, respectively). CONCLUSION: This study provides insight into the clinical presentation and treatment outcomes among patients with cHL in Malaysia. A longer study duration is required to identify OS and PFS benefits and treatment-related complications for different chemotherapeutic regimens.


Subject(s)
B-Lymphocytes , Cohort Studies , Diagnosis , Disease-Free Survival , Drug Therapy , Follow-Up Studies , Germinal Center , Hematologic Neoplasms , Hodgkin Disease , Humans , Lymphoma , Malaysia , Male , Radiotherapy , Retrospective Studies , Sclerosis , Tertiary Care Centers
8.
Blood Research ; : 108-113, 2019.
Article in English | WPRIM (Western Pacific) | ID: wprim-763063

ABSTRACT

BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation (SCT) and can be an alternative to the traditionally-used carmustine. In this study, we aimed to determine the safety and efficacy of bendamustine in the conditioning regimen for autologous SCT in refractory/relapsed lymphomas. METHODS: We designed a descriptive study to evaluate bendamustine in combination with etoposide, cytarabine, and melphalan (BeEAM) in the conditioning regimen for autologous SCT. RESULTS: Fourteen patients (median age, 28 yr) with Hodgkin's lymphoma (HL) (N=8), non-Hodgkin's lymphomas (NHL) (N=5), or peripheral T-cell lymphoma, not otherwise specified (PTCL NOS) (N=1) were included in the study. A median number of 5.95×10⁶ CD34+ cells/kg were transfused. Median times to absolute neutrophil count and platelet engraftment were 17 days and 24 days, respectively. The 100-day transplantation mortality rate was 28% (4 patients). Eight patients (57.14%) had GII-III acute kidney injury, four patients (28.5%) had GIII-IV hyperbilirubinemia, and twelve patients (85%) had GII-III diarrhea. After 3 months, 37% (5 patients) and 21.4% (3 patients) demonstrated complete response and partial response, respectively. The median follow-up was 5.5 months (15 days–19 mo). At the final follow-up, 7 patients (50%) were alive and in CR. CONCLUSION: Our study showed that bendamustine is a potentially toxic agent in the conditioning regimen for autologous SCT, resulting in significant liver, kidney, and gastrointestinal toxicity. Further studies are required to assess its safety and efficacy at reduced doses.


Subject(s)
Acute Kidney Injury , Bendamustine Hydrochloride , Blood Platelets , Carmustine , Cytarabine , Diarrhea , Etoposide , Follow-Up Studies , Hodgkin Disease , Humans , Hyperbilirubinemia , Kidney , Liver , Lymphoma , Lymphoma, Non-Hodgkin , Lymphoma, T-Cell, Peripheral , Melphalan , Mortality , Neutrophils , Stem Cell Transplantation , Stem Cells
9.
Article in Chinese | WPRIM (Western Pacific) | ID: wprim-774353

ABSTRACT

OBJECTIVE@#To analyze the correlation of EBV infection with expression of TNF-α-inducing protein 3 gene and A20 protein in Hodgkin lmphoma.@*METHODS@#The clinical data and pathological specimens of 65 cases of Hodgkin's lymphoma in our hospital were analyzed retrospectively, and the tissue chips were made for the rich area of the tumor cells. The latent membrane protein 1 encoded by EBV was measured by immunohistochemical staining, and the RNA encoded by EBV was measured by in situ hybridization to analyze the infection state. The gene expression of tumor necrosis factor.α-induced protein 3 was detected by fluorescence in situ hybridization, and the expression of A20 protein encoded by EBV was detected by immunohistochemical staining. The obtained data were processed by SPSS 23.0 version statistical software.@*RESULTS@#The positive rate of latent membrane protein 1 was 26.15% (17/65), the positive rate of EBV encoded RNA was 26.15% (17/65), and the coincidence rate was 100.00%. In 65 patients, A20 protein expression was lost in 18 cases (27.69%), and 14 cases (21.54%) showed homozygous or heterozygous deletion of tumor necrosis factorα protein 3 gene. Only 1 case showed A20 loss combined with homozygous deletion of TNFα inducible protein 3. Correlation analysis showed that EBV infection did not significantly relate with expression loss of A20 protein and the gene deletion of TNF-α inducing protein 3 (P>0.05).@*CONCLUSION@#The expression loss of A20 protein and gene detection of TNFα inducing protein 3 are found in both EBV negative and positive patients with Hodgkin's lymphoma, however the results of immunohistochemical staining and fluorescence in situ hybridization are not complete consistant, the reason may closely relate with the technical factors.


Subject(s)
Epstein-Barr Virus Infections , Herpesvirus 4, Human , Hodgkin Disease , Humans , In Situ Hybridization , In Situ Hybridization, Fluorescence , Retrospective Studies , Tumor Necrosis Factor alpha-Induced Protein 3 , Genetics , Viral Matrix Proteins
10.
Rev. colomb. cancerol ; 22(4): 146-150, oct.-dic. 2018. tab, graf
Article in Spanish | LILACS (Americas) | ID: biblio-985456

ABSTRACT

Resumen Entre los linfomas de la zona gris (LZG) encontramos neoplasias con características compartidas entre un linfoma difuso de células B grandes (LDCBG) y un linfoma de Hodgkin clásico (LHC). Lo poco habitual de la patología combinado con la heterogenicidad de la enfermedad, su reciente descripción como entidad específica que conlleva a dificultad y reto diagnóstico, así como la falta de suficiente experiencia terapéutica hacen de la enfermedad una entidad compleja de difícil diagnóstico y reto terapéutico que justifica su descripción continua. Se presenta una paciente con fiebre de un mes sin respuesta al manejo inicial, se estudió y realizó biopsia de ganglio inguinal izquierdo con resultado diagnóstico de LZG con características intermedias entre LDCBG y LHC. Aunque no existen guías establecidas para el manejo de esta entidad, la evidencia actual sugiere mejor respuesta en tratamientos dirigidos a LDCBG, misma terapia empleada en esta paciente con la cual se obtuvo respuesta favorable.


Abstract In the grey zone lymphomas (GZL), there are overlapping characteristics between diffuse large B-cell lymphoma (DLBCL) and classic Hodgkin lymphoma (CHL). The unusual nature of the pathology combined with the heterogeneity of the disease, its recent description as a specific entity, its diagnostic difficulty, and the lack of sufficient therapeutic experience justifies its continuous description. The case is presented of a patient with a fever of one month onset, with no response to initial management. A left inguinal lymph node biopsy reported a diagnosis of GZL with intermediate characteristics between DLBCL and CHL. Although there are no established guidelines for the management of this condition, the current evidence suggests a better response in treatments meant for diffuse large B-cell lymphoma. This same therapy was used in this patient, with a favourable clinical outcome.


Subject(s)
Humans , Therapeutics , Hodgkin Disease , Lymphoma, Large B-Cell, Diffuse , Diagnosis
11.
J. bras. econ. saúde (Impr.) ; 10(2): 118-125, Agosto/2018.
Article in English | LILACS (Americas), ECOS | ID: biblio-914923

ABSTRACT

Background: In 2016, Hodgkin's Lymphoma (HL) was responsible for 2,470 new cases in Brazil and, despite recent scientific advances, there are unmet medical needs that affects patients' outcome. Therefore, we aimed to explore the unmet medical needs in the management of HL patients in Brazil, based on experts' perspective. Methods: A questionnaire was developed to address the unmet medical needs including barriers for the diagnosis and treatment of HL in Brazil. The questionnaire results were presented in a panel discussion to validate participants' responses and to collect additional data. Main results: Eight experts participated in the panel. On both healthcare systems, public and private, a slight majority of patients was women and most of them were under 60 yearsold. In addition, the majority of patients were referred from another specialty on both systems. The time from onco-hematologist appointment to diagnosis was different between public and private sector (median of 30 and 12.5 days, respectively). Most patients in the public sector were on stage III (33%) and IV (33%); in the private sector, most patients were on stages II (36%) and III (24%). The most common barriers were the delayed diagnosis and the unavailability of diagnostic procedures and treatment options. Conclusion: According to participants, issues related to infrastructure and healthcare resource allocation affects the management of HL. Improvements in the infrastructure and educational measures for physicians and patients may contribute to minimize the barriers.


Introdução: Em 2016, o Linfoma de Hodgkin (LH) foi responsável por 2.470 novos casos no Brasil e, apesar dos recentes avanços científicos, há necessidades médicas não atendidas que afetam os pacientes. Portanto, o estudo teve como objetivo explorar as necessidades médicas não atendidas no manejo de pacientes com LH no Brasil, com base na perspectiva de especialistas. Métodos: Um questionário foi desenvolvido para abordar as necessidades médicas não atendidas, incluindo as barreiras para o diagnóstico e tratamento do LH no Brasil. Os resultados do questionário foram apresentados em um painel de discussão para validar as respostas dos participantes e coletar dados adicionais. Principais resultados: Oito especialistas participaram do painel. De acordo com os especialistas, em ambos os sistemas de saúde público e privado, uma pequena maioria dos pacientes era mulher e a maioria tinha menos de 60 anos. Além disso, a maioria dos pacientes foi encaminhada por outra especialidade em ambos os sistemas. O tempo entre a consulta com o onco-hematologista até o diagnóstico foi diferente entre o setor público e privado (mediana de 30 e 12,5 dias, respectivamente). A maioria dos pacientes do setor público apresenta estádios III (33%) e IV (33%); no setor privado, a maioria dos pacientes apresenta estádios II (36%) e III (24%). As barreiras mais comuns foram o atraso no diagnóstico e a indisponibilidade de procedimentos diagnósticos, e opções de tratamento. Conclusão: De acordo com os participantes, as questões relacionadas à infraestrutura e à alocação de recursos de saúde afetam o gerenciamento do LH. Melhorias na infraestrutura e medidas educacionais para médicos e pacientes podem contribuir para minimizar as barreiras.


Subject(s)
Humans , Hodgkin Disease , Patient Care , Health Services Needs and Demand
12.
J. bras. econ. saúde (Impr.) ; 10(2): 172-178, Agosto/2018.
Article in English | LILACS (Americas), ECOS | ID: biblio-915110

ABSTRACT

Background: Hodgkin's Lymphoma (HL) is a curable type of cancer, with a wide variety of therapies, especially for refractory/relapsing cases. Therefore, the study aims to explore the treatment patterns used in the management of HL patients in Brazil. Methods: A survey was developed to explore the treatment patterns in Brazil, addressing topics such as clinical characteristics, lines of therapy, transplant information and cure rates. Then, results were presented in a panel discussion to validate participants' responses and gain additional insights. Main results: The eight experts reported that most patients are women and under 60 years old. In both private and public healthcare systems, ABVD was the most commonly used first-line therapy for patients of all stages. The median cure rates for patients in stages I and II were 80% and 87.5%, and for stages III and IV 60% and 67.5%, respectively, in public and private sectors. For the subsequent lines of therapy, different regimens such as DHAP, GVD, GEV, ICE and allogeneic transplant are used, among others. Brentuximab vedotin was present mainly in the private sector. In the public sector, 70% of the patients are eligible for autologous stem cell transplant; of them, 75% actually receive the transplant. In the private sector, 80% of the patients are eligible, and 100% of them receive the transplant. Conclusion: Similarities were found between the public and private sectors in first-line therapy and cure rates. However, barriers for subsequent lines of therapy are more evident in the public system.


Introdução: O linfoma de Hodgkin (LH) é um tipo de câncer curável, com ampla variedade de terapias, especialmente para casos refratários/recidivantes. Portanto, o estudo visa explorar os padrões de tratamento utilizados no manejo de pacientes com LH no Brasil. Métodos: Uma pesquisa foi desenvolvida para explorar os padrões de tratamento no Brasil, abordando tópicos como: características clínicas, linhas de terapia, informações sobre transplantes e taxas de cura. Em seguida, os resultados foram apresentados em um painel de discussão para validar as respostas dos participantes e coletar os insights adicionais. Principais resultados: Os oito especialistas relataram que maioria dos pacientes é composta por mulheres com idade menor de 60 anos. Em ambos os sistemas de saúde, privado e público, ABVD foi a terapia de primeira linha mais comumente usada para pacientes de todos os estágios. As medianas das taxas de cura para pacientes nos estágios I e II foram de 80% e 87,5%, e para os estádios III e IV, de 60% e 67,5%, nos setores público e privado, respectivamente. Para as linhas subsequentes de terapia, diferentes regimes como DHAP, GVD, GEV, ICE e transplante alogênico são utilizados, entre outros. Brentuximabe vedotina estava presente principalmente no setor privado. No setor público, 70% dos pacientes são elegíveis para transplante autólogo de células-tronco; deles, 75% recebem o transplante. No setor privado, 80% dos pacientes são elegíveis e 100% recebem o transplante. Conclusão: Foram encontradas semelhanças entre o setor público e privado na terapia de primeira linha, bem como nas taxas de cura. No entanto, as barreiras para as linhas subsequentes de terapia são mais evidentes no sistema público.


Subject(s)
Humans , Hodgkin Disease , Health Care Surveys , Drug Therapy
13.
J. bras. econ. saúde (Impr.) ; 10(2): 190-197, Agosto/2018.
Article in English | LILACS (Americas), ECOS | ID: biblio-915117

ABSTRACT

Hodgkin's lymphoma (HL) is a B-cell malignancy with a classical bimodal distribution with incidence peaking in the third and sixth decades of life. The purpose of this review is to describe the current unmet medical need for relapsing/refractory HL and the main data of emerging treatments, including brentuximab vedotin, the immune checkpoint inhibitors nivolumab and pembrolizumab, as well as other compounds in development. Available guidelines for relapsing/refractory HL are discussed.


O linfoma de Hodgkin (LH) é uma neoplasia de células B com distribuição bimodal clássica com pico de incidência na terceira e sexta décadas de vida. O objetivo desta revisão é descrever as atuais necessidades médicas não atendidas dos pacientes com LH recidivante/refratário e os dados principais dos tratamentos emergentes, incluindo brentuximabe vedotina, os inibidores do ponto de verificação imunológico, nivolumabe e pembrolizumabe, bem como outros compostos em desenvolvimento. Além disso, discutem-se as diretrizes disponíveis para LH recidivante/refratário.


Subject(s)
Humans , Hodgkin Disease , Drug Therapy
14.
Blood Research ; : 281-287, 2018.
Article in English | WPRIM (Western Pacific) | ID: wprim-718483

ABSTRACT

BACKGROUND: Bone marrow involvement (BMI) affects the lymphoma stage, survival, and treatment. Bone marrow biopsy (BMB) and fluorodeoxyglucose (FDG) positron emission tomography- computed tomography (PET/CT) are useful techniques to detect BMI. Both have advantages and disadvantages. We aimed to identify factors that could be used to predict BMI with positive and negative results on PET/CT compare them with BMB in newly diagnosed patients with lymphoma. METHODS: We included 22 non-Hodgkin and 16 Hodgkin lymphoma patients in this single center study. All patients had PET/CT examination and BMB before treatment. BMI in BMB was reported as negative or positive. Bone marrow was classified into 3 types by FDG uptake on PT/CT; diffuse involvement, focal involvement, and normal bone marrow. RESULTS: PET/CT and BMB results were concordant (7 positive, 15 negative) in 22 patients (57%). We evaluated concordant and discordant patient characteristics and risk-stratified patients for BMI. Our findings suggest that patients with diffuse FDG uptake on PET/CT, especially patients with advanced age and low platelet and white blood cell counts, are likely to have BMI and could potentially forego BMB. Patients with negative PET/CT findings and no significant laboratory abnormalities are very unlikely to have BMI. CONCLUSION: Our results suggest that BMI should not be decided solely based PET/CT or BMB findings. It is reasonable to use both diagnostic assays along with clinical and laboratory findings. PET/CT result, clinical and laboratory findings could be useful for predicting BMI in patient for whom BMB is contraindicated.


Subject(s)
Biopsy , Blood Platelets , Bone Marrow , Electrons , Hodgkin Disease , Humans , Leukocyte Count , Lymphoma , Positron Emission Tomography Computed Tomography
15.
Article in English | WPRIM (Western Pacific) | ID: wprim-762541

ABSTRACT

BACKGROUND: The South Korean criteria for occupational diseases were amended in July 2013. These criteria included formaldehyde as a newly defined occupational carcinogen, based on cases of “leukemia or nasopharyngeal cancer caused by formaldehyde exposure”. This inclusion was based on the Internal Agency for Research on Cancer classification, which classified formaldehyde as definite human carcinogen for nasopharyngeal cancer in 2004 and leukemia in 2012. METHODS: We reviewed reports regarding the causal relationship between occupational exposure to formaldehyde in Korea and the development of these cancers, in order to determine whether these cases were work-related. RESULTS: Previous reports regarding excess mortality from nasopharyngeal cancer caused by formaldehyde exposure seemed to be influenced by excess mortality from a single plant. The recent meta-risk for nasopharyngeal cancer was significantly increased in case-control studies, but was null for cohort studies (excluding unexplained clusters of nasopharyngeal cancers). A recent analysis of the largest industrial cohort revealed elevated risks of both leukemia and Hodgkin lymphoma at the peak formaldehyde exposure, and both cancers exhibited significant dose-response relationships. A nested case-control study of embalmers revealed that mortality from myeloid leukemia increased significantly with increasing numbers of embalms and with increasing formaldehyde exposure. The recent meta-risks for all leukemia and myeloid leukemia increased significantly. In South Korea, a few cases were considered occupational cancers as a result of mixed exposures to various chemicals (e.g., benzene), although no cases were compensated for formaldehyde exposure. The peak formaldehyde exposure levels in Korea were 2.70–14.8 ppm in a small number of specialized studies, which considered anatomy students, endoscopy employees who handled biopsy specimens, and manufacturing workers who were exposed to high temperatures. CONCLUSION: Additional evidence is needed to confirm the relationship between formaldehyde exposure and nasopharyngeal cancer. All lymphohematopoietic malignancies, including leukemia, should be considered in cases with occupational formaldehyde exposure.


Subject(s)
Biopsy , Case-Control Studies , Classification , Cohort Studies , Endoscopy , Formaldehyde , Hodgkin Disease , Humans , Korea , Leukemia , Leukemia, Myeloid , Mortality , Nasopharyngeal Neoplasms , Occupational Diseases , Occupational Exposure , Plants , Workers' Compensation
16.
São Paulo; s.n; 2018. 95 p.
Thesis in Portuguese | LILACS (Americas) | ID: biblio-970389

ABSTRACT

Introdução: Os linfomas abrangem um grupo heterogêneo de neoplasias originadas no sistema linfático, diferentes quanto à sua histologia, prognóstico e epidemiologia, embora possa haver grande número de aspectos clínicos comuns. De acordo com sua morfologia, dividem-se dois grupos: os linfomas Hodgkin (LH) e os linfomas não-Hodgkin (LNH). Objetivo: Avaliar a tendência temporal da incidência de linfomas no período de 1997 a 2012, identificando a influência de fatores como o sexo, a idade, o período e a coorte e nascimento. Metodologia: Trata-se de um estudo ecológico. Foram obtidas, do Registro de Câncer de Base Populacional de São Paulo (RCBP-SP), informações sobre todos os casos novos de linfomas no Município de São Paulo, diagnosticados no período de 1997 a 2012. Informações sobre o número de habitantes do Município foram obtidas online através do site do Departamento de Informática do SUS. Para avaliar a tendência da incidência de linfomas no decorrer do período, segundo sexo e faixa etária, foram ajustados modelos lineares generalizados (MLG). Para avaliar a influência da idade, do período de diagnóstico e das coortes de nascimento na tendência da incidência dos linfomas, foi utilizado o modelo idade-período-coorte (IPC). Resultados e conclusões: Dos 18.037 casos analisados, 20,5% eram do tipo LH e 79,5% do tipo LNH. Entre os casos de LH, 52,6% eram homens e 70,0% tinham entre 20 e 39 anos. A taxa de incidência de LH padronizada por idade, por 100 mil habitantes, variou de 5,0 em 1997 para 4,0 em 2012, entretanto, não foi detectada nenhuma tendência significativa na incidência ao longo do tempo (p>0,05). O risco de desenvolver LH foi maior no sexo masculino do que no feminino apenas na faixa etária de 0 a 14 anos (p0,05). O risco de desenvolver LH segundo a faixa etária apresentou um padrão etário bimodal. No sexo feminino, os maiores riscos ocorreram nas faixas de 20 a 39 e de 65 anos e mais e, no masculino, nas faixas de 15 a 19 e de 65 anos e mais. O modelo IPC apontou uma influência da coorte de nascimento na incidência de LH em mulheres: para aquelas nascidas antes de 1960, quanto mais antiga a coorte, maior o risco de LH; para as nascidas após 1960, o risco relativo permaneceu estável. Entre os casos de LNH, 51,6% eram homens e 77,4% tinham mais de 40 anos. A taxa de incidência de LNH padronizada por idade, por 100 mil habitantes, passou de 22,6 em 1997 para 17,0 em 2012. Foi detectada uma tendência de decréscimo na incidência de LNH de 1,7% ao ano em todas as faixas etárias, em ambos os sexos (p<0,001). O risco de desenvolver LNH aumentou continuamente com o avançar da idade, em ambos os sexos. O modelo IPC não detectou efeitos de período. Para os homens, as coortes mais velhas apresentam maior risco e, as mais jovens, menor risco. Para as mulheres nascidas antes de 1960 o comportamento foi semelhante ao dos homens, para as nascidas após 1960, o risco relativo permaneceu estável


Introduction: Lymphomas comprise a heterogeneous group of neoplasias originating in the lymphatic system, different in their histology, prognosis and epidemiology, although there may be a large number of common clinical aspects. According to their morphology, two groups are divided: Hodgkin\'s lymphomas (HL) and non-Hodgkin\'s lymphomas (NHL). Objective: To evaluate the temporal trend of the incidence of lymphomas in the period from 1997 to 2012, identifying the influence of factors such as sex, age, period and cohort and birth. Methodology: This is an ecological study. Information about all new cases of lymphomas in the city of São Paulo, diagnosed in the period from 1997 to 2012, were obtained from the São Paulo Population Based Cancer Registry. Information on the number of inhabitants of the Municipality were obtained online through the website of the SUS Department of Informatics. To evaluate the trend of lymphoma incidence during the period, according to sex and age group, generalized linear models (GLM) were adjusted. The age-period-cohort (APC) model was used to evaluate the influence of age, diagnosis period and birth cohorts on the trend of lymphoma incidence. Results and conclusions: Of the 18,037 cases analyzed, 20.5% were HL type and 79.5% NHL type. Among the cases of HL, 52.6% were men and 70.0% were between 20 and 39 years old. The age-standardized incidence rate of HL per 100,000 population ranged from 5.0 in 1997 to 4.0 in 2012, however, no significant trend in incidence over time was detected (p> 0.05). The risk of developing HL was greater in males than in females only in the age group 0 to 14 years (p 0.05). The risk of developing HL according to the age group presented a bimodal age pattern. In females, the highest risks occurred in the 20-39 and 65-year-olds, and in the male, in the 15-19 and 65 years and older ranges. The APC model pointed to an influence of the birth cohort on the incidence of HL in women: for those born before 1960, the older the cohort, the higher the risk of HL; for those born after 1960, the relative risk remained stable. Among the cases of NHL, 51.6% were men and 77.4% were over 40 years old. The age-standardized incidence rate of NHL per 100,000 population increased from 22.6 in 1997 to 17.0 in 2012. A trend of a decrease in the incidence of NHL of 1.7% per year was observed in all ranges in both sexes (p <0.001). The risk of developing NHL increased steadily with advancing age in both sexes. The APC model did not detect period effects. For men, older cohorts are at higher risk, and younger cohorts are at lower risk. For women born before 1960 the behavior was similar to that of men, for those born after 1960, the relative risk remained stable


Subject(s)
Lymphoma, Non-Hodgkin/epidemiology , Hodgkin Disease/epidemiology , Incidence , Linear Models , Age of Onset , Age and Sex Distribution , Ecological Studies
17.
LMJ-Lebanese Medical Journal. 2018; 66 (1): 21-27
in English | IMEMR (Eastern Mediterranean) | ID: emr-170970

ABSTRACT

The 2008 WHO classification is the gold standard for classifying hematopoietic neoplasms. Our study reviewed 1256 cases between the years 2010 and 2014. It aimed to establish a descriptive status of lymphoma cases in Lebanon. Hodgkin lymphomas [HL] accounted for 21% of all cases whereas non-Hodgkin lymphomas [NHL] accounted for 79%. In NHL, mature B-cell neoplasms accounted for 85% and mature T-cell neoplasms accounted for 9%. For mature B-cell neoplasms, the majority of cases [48%] were diffuse large B-cell lymphomas [DLBCL]. Within T-cell lymphomas, anaplastic lymphoma [ALCL 40%] was the most prevalent. The distribution within subtypes confirmed the findings of two previous Lebanese studies. Our figures of HL are higher than in Eastern and Western countries. This could probably be related to EBV infection among other etiologies. Our NHL figures are close to the Western world. Westernization of the way of life of the Lebanese society could explain this result


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Hodgkin Disease/epidemiology , Lymphoma/classification , Lymphoma, Non-Hodgkin/epidemiology , Hematologic Neoplasms/epidemiology , Epidemiology
18.
Journal of Experimental Hematology ; (6): 1072-1078, 2018.
Article in Chinese | WPRIM (Western Pacific) | ID: wprim-689526

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the clinical characteristics and outcome of parhents with EBV infection conbined with hemophagocytic syndrome and Hodgkin's lymphoma.</p><p><b>METHODS</b>The morphotogy of bone marrow cells was observed by bone marrow smear and light microscopy, the pathologic changes of bone marrow ware analyzed by bone marrow biopsy and immunohistochemistry methord, the pathologic changes of lymphonudes ware detected by immunohistochemical methord, the paticnts were treated with ABVD (epirubicin, bleomycin, vincristine and dacarbazine) chemotherapeutic regimen.</p><p><b>RESULTS</b>Fever complicatid with pancytopenia, obvious increase of ferritin and sCD25, hypofibrinogenemia, hemophogocytic phenomen of bone marrow, increase of EBV-DNA copy number ware observed, which all accorded with the criteria EBV righted hemophagocytic syndrome. The curative efficacy of amtiinfective treatmatnt was poor, After treatment with HLH-2004 regimen, the fever symptome and the laboratory indicaters such as whole blood cells, ferritin and fibrinogen all were recovered to normal levels. Left mandibular lymphadenctasis was confirmed as Hodgkin's lymphoma (mixed cell type) by pathological examination. The patient achieved complete molecular remission after 1 course chemotherapy with ABVD regimen. The level of EBV-DNA copy number were also decreased. As the reshlt, the patient's hemophagocytic syndrome had bean effectively controlled, and the Hodgkin's lymphoma is still in complete remission.</p><p><b>CONCLUSION</b>Epstein-Barr virus-ratated hemophagocytic syndrome and Hodgkin's lymphoma are rare, and their long-term prognosis needs to be further explored.</p>


Subject(s)
Epstein-Barr Virus Infections , Herpesvirus 4, Human , Hodgkin Disease , Humans , Lymphohistiocytosis, Hemophagocytic , Vincristine
19.
Rev. bras. hematol. hemoter ; 39(4): 325-330, Oct.-Dec. 2017. tab
Article in English | LILACS (Americas) | ID: biblio-898956

ABSTRACT

Abstract Background: Reports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America. Method: A retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes. Main results: One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries. Conclusion: Patients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.


Subject(s)
Vincristine , Bleomycin , Hodgkin Disease , Doxorubicin , Survival Rate , Dacarbazine , Latin America
20.
Medicina (Ribeiräo Preto) ; 50(5): 317-321, set.-out. 2017. ilus
Article in English | LILACS (Americas) | ID: biblio-910559

ABSTRACT

Study design: case report. Case report: Man, 42 years old, diagnosed with aids two years ago, had developed enlarging in abdominal volume six months from admission. Computed tomography imaging showed free liquid in peritoneal cavity and increased retroperitoneal and mesenteric lymph nodes, besides splenomegaly. Ascitic fluid had milky appearance and high triglycerides levels. Hodgkin's lymphoma (mixed cellularity) was confirmed by histopathological analysis of a video-laparoscopic lymph node biopsy, Ann Arbor IIIS staging. Chemotherapy and continuation of highly active antiretroviral therapy resulted in weight gain and reduction of abdominal volume. Chylous ascites is a rare condition, which has a vast differential diagnosis. Discussion: In our review, the majority (15/18, 83%) of chylous ascites in HIV/aids-patients are due to infectious causes (mainly Mycobacterium avium complex and tuberculosis infection), in highly immunocompromised patients (mean TCD4=87cell/mL). To the best of our knowledge, this is the first case of chylous ascites secondary to Hodgkin's lymphoma in a patient with aids. (AU)


Tipo de estudo: relato de caso. Relato de caso: Homem, 42 anos, diagnosticado com aids há dois anos, desenvolveu aumento de volume abdominal há seis meses da admissão. Tomografia computadorizada mostrou líquido livre na cavidade peritoneal, além de linfonodos mesentéricos e esplenomegalia. O líquido ascítico tinha aspecto leitoso e alto nível de triglicerídeos. Após amplo diagnóstico diferencial, diagnosticamos linfoma de Hodgkin tipo celularidade mista por biópsia linfonodal via videolaparoscópica, Ann Arbor IIIS. Quimioterapia e continuação da terapia antirretroviral de alta potência resultaram em ganho de peso e redução do volume abdominal. Ascite quilosa é uma entidade rara, que possui vários diagnósticos diferenciais. Discussão: Em nossa revisão, a maioria (15/18, 83%) dos casos de ascite quilosa em paciente com HIV/aids deveu-se a causa infecciosa (especialmente pelo Mycobacterium avium complex e tuberculose), em pacientes gravemente imunocomprometidos (linfócitos T-CD4 médio=84células/mm3). Até onde sabemos, este é o primeiro caso de ascite quilosa secundária a linfoma de Hodgkin em paciente com aids. (AU)


Subject(s)
Humans , Male , Adult , Acquired Immunodeficiency Syndrome , Chylous Ascites , Hodgkin Disease , Lymphoma , Lymphoma, AIDS-Related , Venous Thrombosis
SELECTION OF CITATIONS
SEARCH DETAIL